Aspira Women's Health (AWH) Registration Filing summary

Company overview and business model

• Focuses on noninvasive, AI-powered diagnostic tests for gynecologic diseases, with a portfolio including OvaWatch and the OvalPlus workflow, marketed as OvaSuite, for ovarian cancer detection in women with adnexal masses.

• Plans to expand into differential diagnosis of other gynecologic diseases and broaden access through partnerships, decentralized platforms, and advocacy for broader coverage.

• Commercialization efforts include direct sales, partnerships, and the Aspira Synergy platform for international and decentralized test deployment.

Financial performance and metrics

• Recent warrant inducement transaction generated gross proceeds of approximately $2.14 million through the exercise of existing warrants at a reduced price.

• If all new warrants are exercised for cash, potential gross proceeds could reach approximately $3.5 million, though timing and likelihood are uncertain.

• The company is classified as a smaller reporting company, with market value of public float under $700 million and annual revenue below $100 million.

Use of proceeds and capital allocation

• Proceeds from warrant exercises are intended for general working capital and corporate purposes.

• No proceeds will be received from the resale of shares by the selling stockholder; only from cash exercises of warrants.